A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study to Evaluate the Efficacy and Safety of TF0023 Spray Versus Placebo in Functional Improvement of Patients With Ischemic Strokes
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs TF 0023 (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Techfields Pharma
- 05 Mar 2018 Planned End Date changed from 1 May 2018 to 1 May 2020.
- 05 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.
- 10 Jun 2017 Biomarkers information updated